{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T20:03:26Z","timestamp":1783627406204,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1007\/s00105-013-2694-y","type":"journal-article","created":{"date-parts":[[2014,5,12]],"date-time":"2014-05-12T11:42:51Z","timestamp":1399894971000},"page":"415-423","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Schwere arzneimittelinduzierte Hautreaktionen","Severe drug-induced skin reactions"],"prefix":"10.1007","volume":"65","author":[{"given":"M.","family":"Mockenhaupt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,5,11]]},"reference":[{"key":"2694_CR1","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1001\/archderm.138.8.1019","volume":"138","author":"Auquier-Dunant","year":"2002","unstructured":"Auquier-Dunant A, Mockenhaupt M, Naldi L et al (2002) Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis. Arch Dermatol 138:1019\u20131024","journal-title":"Arch Dermatol"},{"key":"2694_CR2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/archderm.139.1.33","volume":"139","author":"Bachot","year":"2003","unstructured":"Bachot N, Revuz J, Roujeau JC (2003) Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. A prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 139:33\u201336","journal-title":"Arch Dermatol"},{"key":"2694_CR3","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","volume":"115","author":"Bastuji-Garin","year":"2000","unstructured":"Bastuji-Garin S, Fouchard N, Bertocchi M et al (2000) SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 115:149\u2013153","journal-title":"J Invest Dermatol"},{"key":"2694_CR4","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","volume":"129","author":"Bastuji-Garin","year":"1993","unstructured":"Bastuji-Garin S, Rzany B, Stern RS et al (1993) Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 129:92\u201396","journal-title":"Arch Dermatol"},{"key":"2694_CR5","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1055\/s-0031-1299530","volume":"229","author":"Chronopoulos","year":"2012","unstructured":"Chronopoulos A, Mockenhaupt M, Pleyer U (2012) Okul\u00e4re Beteiligung bei Stevens-Johnson-Syndrom und Toxisch epidermale Nekrolyse. Klin Monatsbl Augenheilkd 229:534\u2013539","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"2694_CR6","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/nm.1884","volume":"14","author":"Chung","year":"2008","unstructured":"Chung WH, Hung SI, Yang JY et al (2008) Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med 14:1343\u20131350","journal-title":"Nat Med"},{"key":"2694_CR7","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/428486a","volume":"428","author":"Chung","year":"2004","unstructured":"Chung WH, Hung SI, Hong HS et al (2004) A marker for Stevens-Johnson syndrome. Nature 428:486","journal-title":"Nature"},{"key":"2694_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00002030-200109280-00014","volume":"15","author":"Fagot","year":"2001","unstructured":"Fagot JP, Mockenhaupt M, Bouwes Bavinck JN et al (2001) Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis \u2013 preliminary results of a case-control study. AIDS 15:1\u20136","journal-title":"AIDS"},{"key":"2694_CR9","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.2165\/00003495-200565150-00002","volume":"65","author":"Faye","year":"2005","unstructured":"Faye O, Roujeau JC (2005) Treatment of epidermal necrolysis with high-dose intravenous immunoglobulins (IVIG). Clinical experience to date. Drugs 65(15):2085\u20132090","journal-title":"Drugs"},{"key":"2694_CR10","doi-asserted-by":"crossref","unstructured":"Genin E, Chen DP, Hung SI et al (2013) HLA-A*3101 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis. Pharmacogenomics J [Epub ahead of print]","DOI":"10.1038\/tpj.2013.40"},{"key":"2694_CR11","doi-asserted-by":"crossref","first-page":"5","DOI":"10.5070\/D397D8T291","volume":"8","author":"Ghislain","year":"2002","unstructured":"Ghislain PD, Roujeau JC (2002) Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Dermatol Online J 8:5","journal-title":"Dermatol Online J"},{"key":"2694_CR12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/sj.jid.5700404","volume":"126","author":"Grosber","year":"2006","unstructured":"Grosber M, Carsin H, Leclerc F (2006) Epidermal necrolysis in association with mycoplasma pneumoniae infection. Presented at: Meeting on Cutaneous Adverse Drug Reactions and ESDR, Paris, France, 7\u20139. September 2006. J Invest Dermatol 126:23","journal-title":"J Invest Dermatol"},{"key":"2694_CR13","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s40264-013-0070-6","volume":"36","author":"Haddad","year":"2013","unstructured":"Haddad C, Sidoroff A, Kardaun SH et al (2013) Stevens-Johnson syndrome\/toxic epidermal necrolysis: are drug dictionaries correctly informing physicians on the risk? Drug Saf 36:681\u2013686","journal-title":"Drug Saf"},{"key":"2694_CR14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2007.08.036","volume":"58","author":"Halevy","year":"2008","unstructured":"Halevy S, Ghislain PD, Mockenhaupt M et al (2008) Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 58:25\u201332","journal-title":"J Am Acad Dermatol"},{"key":"2694_CR15","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1365-2133.2012.10965.x","volume":"167","author":"Huang","year":"2012","unstructured":"Huang YC, Li YC, Chen TJ (2012) The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis. Br J Dermatol 167:424\u2013432","journal-title":"Br J Dermatol"},{"key":"2694_CR16","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","volume":"102","author":"Hung","year":"2005","unstructured":"Hung SI, Chung WH, Liou LB et al (2005) HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 102:4134\u20134139","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2694_CR17","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/bjd.12501","volume":"169","author":"Kardaun","year":"2013","unstructured":"Kardaun SH, Sekula P, Valeyrie-Allanore L et al (2013) Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol 169:1071\u20131080","journal-title":"Br J Dermatol"},{"key":"2694_CR18","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/bjd.12133","volume":"168","author":"Lipowicz","year":"2013","unstructured":"Lipowicz S, Sekula P, Ingen-Housz-Oro S et al (2013) Prognosis of generalized bullous fixed drug eruption: a case control study. Br J Dermatol 168:726\u2013732","journal-title":"Br J Dermatol"},{"key":"2694_CR19","first-page":"106","volume":"126","author":"Liss","year":"2006","unstructured":"Liss Y, Mockenhaupt M for the RegiSCAR-study group (2006) Erythema exsudativum multiforme majus versus Stevens-Johnson syndrome: differences in clinical pattern and etiology. Presented at: Meeting on Cutaneous Adverse Drug Reactions and ESDR, Paris, France, 7\u20139. September 2006. J Invest Dermatol 126:106","journal-title":"J Invest Dermatol"},{"key":"2694_CR20","first-page":"393","volume":"20","author":"Li\u00df","year":"2012","unstructured":"Li\u00df Y, Mockenhaupt M (2012) Schwere arzneimittelinduzierte Hautreaktionen: Akute generalisierte exanthematische Pustulose und \u201edrug reactions with eosinophilia and systemic symptoms\u201c. Allergo J 20:393\u2013405","journal-title":"Allergo J"},{"key":"2694_CR21","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/sj.tpj.6500356","volume":"6","author":"Lonjou","year":"2006","unstructured":"Lonjou C, Thomas L, Borot N et al (2006) A marker for Stevens-Johnson-syndrome and toxic epidermal necrolysis: ethnicity matters. Pharmacogenomics J 6:265\u2013268","journal-title":"Pharmacogenomics J"},{"key":"2694_CR22","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/FPC.0b013e3282f3ef9c","volume":"18","author":"Lonjou","year":"2008","unstructured":"Lonjou C, Borot N, Sekula P et al (2008) A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 18:99\u2013107","journal-title":"Pharmacogenet Genomics"},{"key":"2694_CR23","doi-asserted-by":"crossref","first-page":"131","DOI":"10.5414\/ALX01508","volume":"35","author":"Mockenhaupt","year":"2012","unstructured":"Mockenhaupt M (2012) Epidemiologie von kutanen Arzneimittelreaktionen. Allergologie 35:131\u2013144","journal-title":"Allergologie"},{"key":"2694_CR24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-0030-1255561","volume":"36","author":"Mockenhaupt","year":"2010","unstructured":"Mockenhaupt M, Li\u00df Y (2010) Schwere bull\u00f6se arzneimittelinduzierte Hautreaktionen. Akt Dermatol 36:1\u201312","journal-title":"Akt Dermatol"},{"key":"2694_CR25","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/j.0022-202X.2005.23642.x","volume":"124","author":"Mockenhaupt","year":"2005","unstructured":"Mockenhaupt M, Idzko M, Grosber M et al (2005) Epidemilogy of staphylococcal scalded skin syndrome in Germany. J Invest Dermatol 124:700\u2013703","journal-title":"J Invest Dermatol"},{"key":"2694_CR26","doi-asserted-by":"crossref","unstructured":"Mockenhaupt M (2009) Severe cutaneous adverse reactions. In: Burgdorf WHC, Plewig G, Wolff HH et al (Hrsg) Braun-Falco\u2019s dermatology. Springer, Heidelberg, S\u00a0473\u2013484","DOI":"10.1007\/978-3-540-29316-3_34"},{"key":"2694_CR27","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","volume":"128","author":"Mockenhaupt","year":"2008","unstructured":"Mockenhaupt M, Viboud C, Dunant A et al (2008) Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 128:35\u201344","journal-title":"J Invest Dermatol"},{"key":"2694_CR28","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1016\/j.jaci.2010.11.046","volume":"127","author":"Phillips","year":"2011","unstructured":"Phillips EJ, Chung WH, Mockenhaupt M et al (2011) Drug hypersensitivity: pharmacogenetics and clinical syndromes. J Allergy Clin Immunol 127(3 Suppl):S60\u2013S66","journal-title":"J Allergy Clin Immunol"},{"key":"2694_CR29","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1016\/j.jaci.2010.11.048","volume":"127","author":"Pichler","year":"2011","unstructured":"Pichler WJ, Naisbitt DJ, Park BK (2011) Immune pathomechanism of drug hypersensitivity reactions. J Allergy Clin Immunol 127(3 Suppl):S74\u2013S81","journal-title":"J Allergy Clin Immunol"},{"key":"2694_CR30","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","volume":"333","author":"Roujeau","year":"1995","unstructured":"Roujeau JC, Kelly JP, Naldi L et al (1995) Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 333:1600\u20131607","journal-title":"N Engl J Med"},{"key":"2694_CR31","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2133.1996.tb03598.x","volume":"135","author":"Rzany","year":"1996","unstructured":"Rzany B, Hering O, Mockenhaupt M et al (1996) Histopathological and epidemiological characteristics of patients with erythema exsudativum multiforme majus (EEMM), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Br J Dermatol 135:6\u201311","journal-title":"Br J Dermatol"},{"key":"2694_CR32","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/0895-4356(96)00035-2","volume":"49","author":"Rzany","year":"1996","unstructured":"Rzany B, Mockenhaupt M, Baur S et al (1996) Epidemiology of erythema exsudativum multiforme majus (EEMM), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in Germany (1990\u20131992). Structure and results of a population-based registry. J Clin Epidemiol 49:769\u2013773","journal-title":"J Clin Epidemiol"},{"key":"2694_CR33","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/j.1365-2133.1997.tb03667.x","volume":"136","author":"Salopek","year":"1997","unstructured":"Salopek TG (1997) Nikolsky\u2019s sign: is it \u201edry\u201c or is it \u201ewet\u201c? Br J Dermatol 136:762\u2013767","journal-title":"Br J Dermatol"},{"key":"2694_CR34","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/clpt.2009.252","volume":"88","author":"Sassolas","year":"2010","unstructured":"Sassolas B, Haddad C, Mockenhaupt M et al (2010) ALDEN an algorithm for assessment of drug causality in Stevens-Johnson-syndrome and toxic epidermal necrolysis. Comparison with case-control analysis. Clin Pharmacol Ther 88:60\u201368","journal-title":"Clin Pharmacol Ther"},{"key":"2694_CR35","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jaad.2007.08.039","volume":"58","author":"Schneck","year":"2008","unstructured":"Schneck J, Fagot JP, Sekula P et al (2008) Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol 58:33\u201340","journal-title":"J Am Acad Dermatol"},{"key":"2694_CR36","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/jid.2012.510","volume":"133","author":"Sekula","year":"2013","unstructured":"Sekula P, Dunant A, Mockenhaupt M et al (2013) Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol 133:1197\u20131204","journal-title":"J Invest Dermatol"},{"key":"2694_CR37","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s00134-009-1659-1","volume":"36","author":"Struck","year":"2010","unstructured":"Struck MF, Hilbert P, Mockenhaupt M et al (2010) Severe cutaneous adverse reactions: emergency approach to non-burn epidermolytic syndromes. Intensive Care Med 36:22\u201332","journal-title":"Intensive Care Med"},{"key":"2694_CR38","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/j.1365-2133.2010.09863.x","volume":"163","author":"Valeyrie-Allanore","year":"2010","unstructured":"Valeyrie-Allanore L, Wolkenstein P, Brochard L et al (2010) Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 163:847\u2013853","journal-title":"Br J Dermatol"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-013-2694-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-013-2694-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-013-2694-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T12:31:10Z","timestamp":1648989070000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-013-2694-y"}},"subtitle":["Stevens-Johnson-Syndrom und toxisch epidermale Nekrolyse","Stevens-Johnson syndrome and toxic epidermal necrolysis"],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["2694"],"URL":"https:\/\/doi.org\/10.1007\/s00105-013-2694-y","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5]]}}}